For primary prevention patients at high risk, such as those with a 10-year risk > 10%, the LDL target is less than 70 mg/dL (class 2a recommendation). For this group, treatment begins with a ...

Lipid-lowering therapy can be considered with a 10-year PREVENT-ASCVD risk estimate of 3% to <5% (borderline) and should be considered for those at 5% to <10% (intermediate) 10-year risk. For ...

Choices for pharmacologic therapy should be guided by a 10-year global risk assessment score for ASCVD or coronary heart disease using established risk equations (eg, the Framingham risk calculator, ...

Findings showed treatment with inclisiran led to clinically meaningful and statistically significant LDL-C lowering compared with placebo and ezetimibe. Topline results were announced from the phase 3 ...

Compared with high-intensity statin therapy, moderate intensity statin therapy plus ezetimibe was equally effective in preventing CV events among patients undergoing PCI. Moderate-intensity statin ...

Statins are among the most commonly prescribed medications for reducing high cholesterol and lowering the risk of heart attack and stroke. People searching for popular statin medications are often ...

People living with HIV have a significantly increased risk of cardiovascular disease that requires a different level of preventive management than in the general population. Last year, an HHS panel ...

Patients who received high-intensity statin therapy had a 23% elevated risk for developing type 2 diabetes (T2D) compared to those on low-intensity statins, the results of a large study showed. In ...